Genprex Secures Canadian Patent for Reqorsa® Combination Therapy in Lung Cancer
Event summary
- Genprex received a Notice of Allowance from CIPO for a patent covering Reqorsa® gene therapy combined with PD-1 or PD-L1 antibodies to treat NSCLC and SCLC.
- The patent strengthens Genprex's IP portfolio, complementing existing patents in 12 other countries.
- Reqorsa® is being evaluated in the Acclaim-3 trial alongside Genentech’s Tecentriq® for extensive stage small cell lung cancer (ES-SCLC).
- Lung cancer is the leading cause of cancer death in Canada, with 32,900 new cases and 19,300 deaths expected in 2026.
The big picture
Genprex’s patent expansion in Canada reinforces its competitive edge in lung cancer therapeutics, a critical market given the high prevalence and mortality rates of the disease. The strategic combination of Reqorsa® with PD-1/PD-L1 inhibitors aligns with the growing trend of immuno-oncology therapies, positioning Genprex to capitalize on unmet medical needs in both NSCLC and SCLC.
What we're watching
- Clinical Trial Progress
- The pace at which the Acclaim-3 trial advances, particularly the interim analysis after the 25th patient reaches 18 weeks of follow-up.
- Regulatory Strategy
- How Genprex leverages this patent in Canada alongside existing global IP protections to strengthen its market position.
- Commercialization Pathway
- Whether the combination therapy can demonstrate superior efficacy over existing treatments, paving the way for broader adoption.
Related topics